Clinical Trial Update: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-human study of the SHP2 inhibitor BBP-398 in advanced solid tumors has been terminated (Phase 1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• BBP-398

Snippet

Sponsor: Navire Pharma Inc., a BridgeBio company | Conditions: Tumor, Solid | Phase 1 | Status: TERMINATED